Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada
•outcomes were not different for HLA-B27 CLL patients with/without spondyloarthritis.•HLA-B27 does not influence clinical course of CLL patients for marrow transplant.•Routine HLA-B27 testing in CLL/SLL not warranted. Human leukocyte antigen B27 (HLA-B27), associated with spondyloarthritis, was sugg...
Gespeichert in:
| Veröffentlicht in: | Leukemia research 2019-09, Vol.84, p.106193-106193, Article 106193 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 106193 |
|---|---|
| container_issue | |
| container_start_page | 106193 |
| container_title | Leukemia research |
| container_volume | 84 |
| creator | Huang, Steven J. Chan, Jonathan Bruyère, Helene Allan, Lenka L. Gerrie, Alina S. Toze, Cynthia L. |
| description | •outcomes were not different for HLA-B27 CLL patients with/without spondyloarthritis.•HLA-B27 does not influence clinical course of CLL patients for marrow transplant.•Routine HLA-B27 testing in CLL/SLL not warranted.
Human leukocyte antigen B27 (HLA-B27), associated with spondyloarthritis, was suggested to be protective against chronic lymphocytic leukemia (CLL). It is hypothesized that HLA-B27 patients may have worse outcome in part related to their other comorbidities.
We sought to compare the clinical characteristics and outcomes of CLL and small lymphocytic lymphoma (SLL) patients referred for allogeneic hematopoietic stem cell transplantation (allo-HSCT) based on their HLA-B27 status.
This retrospective population-based case series analyzed CLL/SLL patients who were HLA-typed for potential allo-HSCT in British Columbia, Canada.
of 279 CLL/SLL patients referred for potential allo-HSCT, 34 patients were HLA-B27 positive. For HLA-B27 patients, median age at CLL diagnosis was 53.5 years (range, 27–67) and 71% were male. Seven patients had 11q deletion and nine patients had 17p deletion detected prior to first CLL therapy or at relapse. Eleven HLA-B27 patients received allo-HSCT. Two patients developed acute myeloid leukemia. One patient with ankylosing spondylitis had Richter’s transformation prior to any CLL therapy. Spondyloarthritis-related disorders were diagnosed in 12 HLA-B27 patients but there was no temporal correlation with development of CLL. Overall survival (OS) and treatment-free survival (TFS) were not significantly different between HLA-B27 patients with or without spondyloarthritis-related disorders. There were no significant differences in clinical characteristics at CLL diagnosis or OS/TFS between HLA-B27 positive and negative patients referred for allo-HSCT.
HLA-B27 positivity does not appear to influence outcome for CLL/SLL patients referred for allo-HSCT. Further studies are needed to evaluate the clinical significance of HLA-B27 in a general CLL population. |
| doi_str_mv | 10.1016/j.leukres.2019.106193 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2261976255</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0145212619301389</els_id><sourcerecordid>2261976255</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-be7462f5a02f8af7a2fd80f859eada87b364a16273a16d3d67724c03ebb9e1f63</originalsourceid><addsrcrecordid>eNqFkctu1DAUhiMEokPhEUBnyaIZYnucCxvUjgpFGgkJwdpynBPiwYmDj9NqHpZ3qYcZ2LKxLfu_6PjLstesWLOCle_2a4fLz4C05gVr0l3JGvEkW7G6ErmshXyarQq2kTlnvLzIXhDti6KQDWueZxeCCS4rwVbZ7-0Q_GQNuMM4D94c4vGcknG0GmYdLU6R4MHGAe521_kNryBgjyFgB70PoJ3zP3DCZBtw1NHP3uIxhCKOYNA5iEFPNDs9xRTnJ-g8TD7CoO8RHnwgBL9E40ek9_AVaXGp0PeQ6v28uD-evNWUCk1agTBYJNCTdgeyBHaCm2CjpQG23i1ja_UVbNNzp19mz3rtCF-d98vs-8fbb9u7fPfl0-ft9S43opQxb7HalLyXuuB9rftK876ri76WDaaQumpFudGs5JVIaye6sqr4xhQC27ZB1pfiMnt7yp2D_7UgRTVaOs6uJ_QLKc4TnarkUiapPElN8ETpK9Uc7KjDQbFCHcmqvTqTVUey6kQ2-d6cK5Z2xO6f6y_KJPhwEmAa9N5iUGQSPIOdDWii6rz9T8Uj5fa9Tw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2261976255</pqid></control><display><type>article</type><title>Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Huang, Steven J. ; Chan, Jonathan ; Bruyère, Helene ; Allan, Lenka L. ; Gerrie, Alina S. ; Toze, Cynthia L.</creator><creatorcontrib>Huang, Steven J. ; Chan, Jonathan ; Bruyère, Helene ; Allan, Lenka L. ; Gerrie, Alina S. ; Toze, Cynthia L.</creatorcontrib><description>•outcomes were not different for HLA-B27 CLL patients with/without spondyloarthritis.•HLA-B27 does not influence clinical course of CLL patients for marrow transplant.•Routine HLA-B27 testing in CLL/SLL not warranted.
Human leukocyte antigen B27 (HLA-B27), associated with spondyloarthritis, was suggested to be protective against chronic lymphocytic leukemia (CLL). It is hypothesized that HLA-B27 patients may have worse outcome in part related to their other comorbidities.
We sought to compare the clinical characteristics and outcomes of CLL and small lymphocytic lymphoma (SLL) patients referred for allogeneic hematopoietic stem cell transplantation (allo-HSCT) based on their HLA-B27 status.
This retrospective population-based case series analyzed CLL/SLL patients who were HLA-typed for potential allo-HSCT in British Columbia, Canada.
of 279 CLL/SLL patients referred for potential allo-HSCT, 34 patients were HLA-B27 positive. For HLA-B27 patients, median age at CLL diagnosis was 53.5 years (range, 27–67) and 71% were male. Seven patients had 11q deletion and nine patients had 17p deletion detected prior to first CLL therapy or at relapse. Eleven HLA-B27 patients received allo-HSCT. Two patients developed acute myeloid leukemia. One patient with ankylosing spondylitis had Richter’s transformation prior to any CLL therapy. Spondyloarthritis-related disorders were diagnosed in 12 HLA-B27 patients but there was no temporal correlation with development of CLL. Overall survival (OS) and treatment-free survival (TFS) were not significantly different between HLA-B27 patients with or without spondyloarthritis-related disorders. There were no significant differences in clinical characteristics at CLL diagnosis or OS/TFS between HLA-B27 positive and negative patients referred for allo-HSCT.
HLA-B27 positivity does not appear to influence outcome for CLL/SLL patients referred for allo-HSCT. Further studies are needed to evaluate the clinical significance of HLA-B27 in a general CLL population.</description><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/j.leukres.2019.106193</identifier><identifier>PMID: 31325731</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Alleles ; Ankylosing spondylitis ; British Columbia - epidemiology ; Case series ; Case-Control Studies ; CLL ; Comorbidity ; Female ; Hematopoietic Stem Cell Transplantation ; HLA-B27 ; HLA-B27 Antigen - genetics ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology ; Leukemia, Lymphocytic, Chronic, B-Cell - genetics ; Leukemia, Lymphocytic, Chronic, B-Cell - mortality ; Leukemia, Lymphocytic, Chronic, B-Cell - therapy ; Male ; Middle Aged ; Outcome ; Prognosis ; Public Health Surveillance ; Spondyloarthritis ; Survival Analysis ; Transplantation, Homologous ; Treatment Outcome</subject><ispartof>Leukemia research, 2019-09, Vol.84, p.106193-106193, Article 106193</ispartof><rights>2019 Elsevier Ltd</rights><rights>Copyright © 2019 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-be7462f5a02f8af7a2fd80f859eada87b364a16273a16d3d67724c03ebb9e1f63</citedby><cites>FETCH-LOGICAL-c365t-be7462f5a02f8af7a2fd80f859eada87b364a16273a16d3d67724c03ebb9e1f63</cites><orcidid>0000-0002-8553-2246</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0145212619301389$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31325731$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Steven J.</creatorcontrib><creatorcontrib>Chan, Jonathan</creatorcontrib><creatorcontrib>Bruyère, Helene</creatorcontrib><creatorcontrib>Allan, Lenka L.</creatorcontrib><creatorcontrib>Gerrie, Alina S.</creatorcontrib><creatorcontrib>Toze, Cynthia L.</creatorcontrib><title>Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>•outcomes were not different for HLA-B27 CLL patients with/without spondyloarthritis.•HLA-B27 does not influence clinical course of CLL patients for marrow transplant.•Routine HLA-B27 testing in CLL/SLL not warranted.
Human leukocyte antigen B27 (HLA-B27), associated with spondyloarthritis, was suggested to be protective against chronic lymphocytic leukemia (CLL). It is hypothesized that HLA-B27 patients may have worse outcome in part related to their other comorbidities.
We sought to compare the clinical characteristics and outcomes of CLL and small lymphocytic lymphoma (SLL) patients referred for allogeneic hematopoietic stem cell transplantation (allo-HSCT) based on their HLA-B27 status.
This retrospective population-based case series analyzed CLL/SLL patients who were HLA-typed for potential allo-HSCT in British Columbia, Canada.
of 279 CLL/SLL patients referred for potential allo-HSCT, 34 patients were HLA-B27 positive. For HLA-B27 patients, median age at CLL diagnosis was 53.5 years (range, 27–67) and 71% were male. Seven patients had 11q deletion and nine patients had 17p deletion detected prior to first CLL therapy or at relapse. Eleven HLA-B27 patients received allo-HSCT. Two patients developed acute myeloid leukemia. One patient with ankylosing spondylitis had Richter’s transformation prior to any CLL therapy. Spondyloarthritis-related disorders were diagnosed in 12 HLA-B27 patients but there was no temporal correlation with development of CLL. Overall survival (OS) and treatment-free survival (TFS) were not significantly different between HLA-B27 patients with or without spondyloarthritis-related disorders. There were no significant differences in clinical characteristics at CLL diagnosis or OS/TFS between HLA-B27 positive and negative patients referred for allo-HSCT.
HLA-B27 positivity does not appear to influence outcome for CLL/SLL patients referred for allo-HSCT. Further studies are needed to evaluate the clinical significance of HLA-B27 in a general CLL population.</description><subject>Adult</subject><subject>Aged</subject><subject>Alleles</subject><subject>Ankylosing spondylitis</subject><subject>British Columbia - epidemiology</subject><subject>Case series</subject><subject>Case-Control Studies</subject><subject>CLL</subject><subject>Comorbidity</subject><subject>Female</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>HLA-B27</subject><subject>HLA-B27 Antigen - genetics</subject><subject>Humans</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - genetics</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Outcome</subject><subject>Prognosis</subject><subject>Public Health Surveillance</subject><subject>Spondyloarthritis</subject><subject>Survival Analysis</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctu1DAUhiMEokPhEUBnyaIZYnucCxvUjgpFGgkJwdpynBPiwYmDj9NqHpZ3qYcZ2LKxLfu_6PjLstesWLOCle_2a4fLz4C05gVr0l3JGvEkW7G6ErmshXyarQq2kTlnvLzIXhDti6KQDWueZxeCCS4rwVbZ7-0Q_GQNuMM4D94c4vGcknG0GmYdLU6R4MHGAe521_kNryBgjyFgB70PoJ3zP3DCZBtw1NHP3uIxhCKOYNA5iEFPNDs9xRTnJ-g8TD7CoO8RHnwgBL9E40ek9_AVaXGp0PeQ6v28uD-evNWUCk1agTBYJNCTdgeyBHaCm2CjpQG23i1ja_UVbNNzp19mz3rtCF-d98vs-8fbb9u7fPfl0-ft9S43opQxb7HalLyXuuB9rftK876ri76WDaaQumpFudGs5JVIaye6sqr4xhQC27ZB1pfiMnt7yp2D_7UgRTVaOs6uJ_QLKc4TnarkUiapPElN8ETpK9Uc7KjDQbFCHcmqvTqTVUey6kQ2-d6cK5Z2xO6f6y_KJPhwEmAa9N5iUGQSPIOdDWii6rz9T8Uj5fa9Tw</recordid><startdate>201909</startdate><enddate>201909</enddate><creator>Huang, Steven J.</creator><creator>Chan, Jonathan</creator><creator>Bruyère, Helene</creator><creator>Allan, Lenka L.</creator><creator>Gerrie, Alina S.</creator><creator>Toze, Cynthia L.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8553-2246</orcidid></search><sort><creationdate>201909</creationdate><title>Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada</title><author>Huang, Steven J. ; Chan, Jonathan ; Bruyère, Helene ; Allan, Lenka L. ; Gerrie, Alina S. ; Toze, Cynthia L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-be7462f5a02f8af7a2fd80f859eada87b364a16273a16d3d67724c03ebb9e1f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alleles</topic><topic>Ankylosing spondylitis</topic><topic>British Columbia - epidemiology</topic><topic>Case series</topic><topic>Case-Control Studies</topic><topic>CLL</topic><topic>Comorbidity</topic><topic>Female</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>HLA-B27</topic><topic>HLA-B27 Antigen - genetics</topic><topic>Humans</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - genetics</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Outcome</topic><topic>Prognosis</topic><topic>Public Health Surveillance</topic><topic>Spondyloarthritis</topic><topic>Survival Analysis</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Steven J.</creatorcontrib><creatorcontrib>Chan, Jonathan</creatorcontrib><creatorcontrib>Bruyère, Helene</creatorcontrib><creatorcontrib>Allan, Lenka L.</creatorcontrib><creatorcontrib>Gerrie, Alina S.</creatorcontrib><creatorcontrib>Toze, Cynthia L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Steven J.</au><au>Chan, Jonathan</au><au>Bruyère, Helene</au><au>Allan, Lenka L.</au><au>Gerrie, Alina S.</au><au>Toze, Cynthia L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2019-09</date><risdate>2019</risdate><volume>84</volume><spage>106193</spage><epage>106193</epage><pages>106193-106193</pages><artnum>106193</artnum><issn>0145-2126</issn><eissn>1873-5835</eissn><abstract>•outcomes were not different for HLA-B27 CLL patients with/without spondyloarthritis.•HLA-B27 does not influence clinical course of CLL patients for marrow transplant.•Routine HLA-B27 testing in CLL/SLL not warranted.
Human leukocyte antigen B27 (HLA-B27), associated with spondyloarthritis, was suggested to be protective against chronic lymphocytic leukemia (CLL). It is hypothesized that HLA-B27 patients may have worse outcome in part related to their other comorbidities.
We sought to compare the clinical characteristics and outcomes of CLL and small lymphocytic lymphoma (SLL) patients referred for allogeneic hematopoietic stem cell transplantation (allo-HSCT) based on their HLA-B27 status.
This retrospective population-based case series analyzed CLL/SLL patients who were HLA-typed for potential allo-HSCT in British Columbia, Canada.
of 279 CLL/SLL patients referred for potential allo-HSCT, 34 patients were HLA-B27 positive. For HLA-B27 patients, median age at CLL diagnosis was 53.5 years (range, 27–67) and 71% were male. Seven patients had 11q deletion and nine patients had 17p deletion detected prior to first CLL therapy or at relapse. Eleven HLA-B27 patients received allo-HSCT. Two patients developed acute myeloid leukemia. One patient with ankylosing spondylitis had Richter’s transformation prior to any CLL therapy. Spondyloarthritis-related disorders were diagnosed in 12 HLA-B27 patients but there was no temporal correlation with development of CLL. Overall survival (OS) and treatment-free survival (TFS) were not significantly different between HLA-B27 patients with or without spondyloarthritis-related disorders. There were no significant differences in clinical characteristics at CLL diagnosis or OS/TFS between HLA-B27 positive and negative patients referred for allo-HSCT.
HLA-B27 positivity does not appear to influence outcome for CLL/SLL patients referred for allo-HSCT. Further studies are needed to evaluate the clinical significance of HLA-B27 in a general CLL population.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>31325731</pmid><doi>10.1016/j.leukres.2019.106193</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-8553-2246</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0145-2126 |
| ispartof | Leukemia research, 2019-09, Vol.84, p.106193-106193, Article 106193 |
| issn | 0145-2126 1873-5835 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2261976255 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Alleles Ankylosing spondylitis British Columbia - epidemiology Case series Case-Control Studies CLL Comorbidity Female Hematopoietic Stem Cell Transplantation HLA-B27 HLA-B27 Antigen - genetics Humans Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology Leukemia, Lymphocytic, Chronic, B-Cell - genetics Leukemia, Lymphocytic, Chronic, B-Cell - mortality Leukemia, Lymphocytic, Chronic, B-Cell - therapy Male Middle Aged Outcome Prognosis Public Health Surveillance Spondyloarthritis Survival Analysis Transplantation, Homologous Treatment Outcome |
| title | Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T15%3A27%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20lymphocytic%20leukemia%20patients%20with%20HLA-B27%20referred%20for%20allogeneic%20hematopoietic%20stem%20cell%20transplantation%20do%20not%20have%20worse%20outcomes:%20Results%20of%20a%20population-based%20case%20series%20analysis%20in%20British%20Columbia,%20Canada&rft.jtitle=Leukemia%20research&rft.au=Huang,%20Steven%20J.&rft.date=2019-09&rft.volume=84&rft.spage=106193&rft.epage=106193&rft.pages=106193-106193&rft.artnum=106193&rft.issn=0145-2126&rft.eissn=1873-5835&rft_id=info:doi/10.1016/j.leukres.2019.106193&rft_dat=%3Cproquest_cross%3E2261976255%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2261976255&rft_id=info:pmid/31325731&rft_els_id=S0145212619301389&rfr_iscdi=true |